Payment overview · 2025
General Payments
$1,318.52
23 reported records · 9 companies
Healthcare provider profile · identity verified
Maian Ye, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · SAN FRANCISCO, CA · NPI 1912198110
Verified facts
What the public records show
CMS Open Payments records show Maian Ye, DO received $1,318.52 in general payments during 2025 across 23 reported records.
GlaxoSmithKline, LLC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Aranesp by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $289.52 | 22.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.37 | 19.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.00 | 11.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.94 | 10.4% | 8 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $129.83 | 9.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $122.39 | 9.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $104.16 | 7.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.64 | 7.6% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $23.67 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,318.52 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $231.98 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $136.94 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $136.38 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $122.39 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $120.63 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.54 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $23.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 284 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
284 | 94 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | 15 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1021 | 345 |
| Tamsulosin Hcl | Tamsulosin Hcl | 589 | 220 |
| Febuxostat | Febuxostat | 444 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 157 |
| Losartan Potassium | Losartan Potassium | 436 | 155 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 130 |
| Metformin Hcl | Metformin Hcl | 322 | 109 |
| Farxiga | Dapagliflozin Propanediol | 284 | 94 |
| Jardiance | Empagliflozin | 271 | 80 |
| Prosol | Parenteral Amino Acid 20% No.1 | 238 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 218 | 82 |
| Simvastatin | Simvastatin | 182 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 84 |
| Finasteride | Finasteride | 162 | 66 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 162 | 92 |
| Furosemide | Furosemide | 158 | 70 |
| Alendronate Sodium | Alendronate Sodium | 154 | 57 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 134 | 55 |
| Famotidine | Famotidine | 122 | 56 |
| Allopurinol | Allopurinol | 112 | 47 |
| Nifedipine Er | Nifedipine | 108 | 41 |
| Lisinopril | Lisinopril | 107 | 37 |
| Eliquis | Apixaban | 106 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 106 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 37 |
| Dutasteride | Dutasteride | 95 | 30 |
| Tradjenta | Linagliptin | 95 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 25 |
| Gabapentin | Gabapentin | 80 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 30 |
| Glipizide | Glipizide | 78 | 26 |
| Sevelamer Carbonate | Sevelamer Carbonate | 75 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 22 |
| Omeprazole | Omeprazole | 71 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 22 |
| Azithromycin | Azithromycin | 63 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 60 | 48 |
| Januvia | Sitagliptin Phosphate | 60 | 23 |
| Atenolol | Atenolol | 59 | 19 |
| Benazepril Hcl | Benazepril Hcl | 57 | 20 |
| Gemtesa | Vibegron | 54 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 19 |
| Calcium Acetate | Calcium Acetate | 52 | 23 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Metformin Hcl Er | Metformin Hcl | 49 | 20 |
| Procrit | Epoetin Alfa | 49 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 16 |
| Glipizide Er | Glipizide | 46 | 18 |
| Fluocinonide | Fluocinonide | 45 | 23 |
| Carvedilol | Carvedilol | 44 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 24 |
| Lovastatin | Lovastatin | 44 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 38 |
| Meclizine Hcl | Meclizine Hcl | 38 | 27 |
| Memantine Hcl | Memantine Hcl | 38 | 12 |
| Linzess | Linaclotide | 35 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 35 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Ibuprofen | Ibuprofen | 34 | 32 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Lansoprazole | Lansoprazole | 33 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 15 |
| Calcitriol | Calcitriol | 32 | 13 |
| Telmisartan | Telmisartan | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 21 |
| Hydrocortisone | Hydrocortisone | 29 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | 15 |
| Potassium Citrate Er | Potassium Citrate | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | 19 |
| Chlorthalidone | Chlorthalidone | 24 | 12 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | 14 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Colchicine | Colchicine | 22 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Potassium Chloride | Potassium Chloride | 22 | 11 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | 12 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 11 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | 11 |
| Lorazepam | Lorazepam | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Celecoxib | Celecoxib | 13 | 12 |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Retacrit | Epoetin Alfa-Epbx | 13 | suppressed |
| Tarpeyo | Budesonide | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,318.52 · 23 records | GlaxoSmithKline, LLC. | ACTHAR, AREXVY, FARXIGA, Filspari, Kerendia, LINZESS, Ozempic, TAVNEOS, TRELEGY ELLIPTA, Wegovy, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error